SEOUL, South Korea, Jan. 11, 2026 /PRNewswire/ — Jeju-based ingredient manufacturer suchang announced that it is strengthening the supply of Jeju mandarin chenpi to Indonesia by engaging with local partners through health food exhibitions and B2B business consultations in the country.
Chenpi refers to traditionally dried mandarin peel and is supplied to food manufacturers both in Korea and overseas for its distinctive citrus aroma and functional health properties. In traditional herbal medicine, chenpi has long been used as an ingredient associated with digestive support, antioxidant activity, and vascular health benefits, making it a widely utilized raw material for health-oriented products.
As consumer demand in Indonesia increases for naturally derived food and beverage products and plant-based health supplements, OEM manufacturers and food additive producers are showing growing interest in Jeju-sourced chenpi. In particular, the active development of wellbeing beverages, traditional tea-based products, and functional drinks using natural extracts has expanded the range of potential applications for mandarin peel ingredients.
Refined dried citrus peel contains bioactive compounds such as hesperidin and flavonoids, which are known to support digestion and help strengthen immune health. These functional components have positioned chenpi as a versatile ingredient across multiple food and beverage categories.
A suchang representative stated, “Chenpi is a natural ingredient that offers both the unique flavor of mandarin citrus and functional health benefits, aligning well with Indonesia’s growing emphasis on clean-label and naturally sourced products.” The company plans to enhance its global presence by establishing long-term supply systems and expanding product diversification in international markets.

Đề xuất
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Nexalin Technology Receives Nasdaq Listing Status Notification
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity
CAPNOS LEGURA Vape Replacement Investigated: 2026 Consumer Analysis Examines Nicotine-Free Behavioral Aid Technology and Safety Documentation
CNEY Receives Nasdaq Delisting Determination for Minimum Bid Price Deficiency